Other Neoplasms and Rare Cancers

Other Neoplasms and Rare Cancers includes cell line models derived from uncommon, diagnostically complex, or less frequently represented tumor types. This category covers cell lines associated with rare malignant and non-malignant neoplasms, including acinar neoplasm, rhabdoid tumor, hepatoblastoma, malignant granulosa cell tumor, Leydig cell tumor, chordoma, and sacral chordoma. It also includes certain broadly classified malignant tumors or neoplasms when the original diagnosis is not assigned to a more specific cancer category.

These rare cancer cell lines provide useful in vitro models for studying tumor biology, lineage-specific differentiation, oncogenic signaling, drug response, and disease mechanisms in cancers that are often underrepresented in standard cell line collections. For example, hepatoblastoma models support pediatric liver cancer research, chordoma and sacral chordoma cell lines are relevant for studies of notochord-derived tumors, and sex cord-stromal tumor models such as granulosa cell tumor and Leydig cell tumor cell lines can be used to investigate endocrine-related tumor biology.

Because rare neoplasms often have limited clinical sample availability, well-characterized cell line models can help researchers explore cancer progression, molecular pathways, therapeutic sensitivity, and biomarker development. This category may also include models relevant to hereditary cancer predisposition, such as BRCA1-associated research contexts, where tumor cells or genetically defined cell models are used to study DNA repair, genomic instability, and cancer susceptibility.

Ascent Research provides rare cancer and other neoplasm cell lines for research applications including cancer biology, drug screening, pathway analysis, tumor classification studies, and translational oncology research. Researchers seeking specific tumor origins, mutation backgrounds, or diagnostic classifications are encouraged to contact Ascent Research for available product details and supporting information.